? ?Fexuprazan (CAS 1902954-60-2) | Next-Gen Potassium-Competitive Acid Blocker (P-CAB) for Gastrointestinal Disorders? ?

?? ?Product Overview?

?Fexuprazan? (CAS 1902954-60-2), also known as ?Abeprazan?, is a ?potassium-competitive acid blocker (P-CAB)? with the molecular formula ?C??H??F?N?O?S? and molecular weight ?410.41?. This high-purity white to off-white crystalline powder (≥95% HPLC) is designed for ?acid-related gastrointestinal therapies?, including ?erosive esophagitis? and ?peptic ulcer disease?. Developed by Daewoong Pharmaceuticals, it offers rapid and sustained acid suppression by inhibiting H+/K+-ATPase, outperforming traditional proton pump inhibitors (PPIs) in symptom relief and mucosal healing.

?Key Functions?:

• Accelerates ?erosive esophagitis healing? and reduces recurrence risk.

• Enhances ?Helicobacter pylori eradication? in combination therapies.

• Acts as a ?pharmaceutical intermediate? for advanced P-CAB formulations.

?Target Industries?: Pharmaceutical manufacturing, clinical research, biotechnology.

? ?Key Advantages?

?? ?Applications?

• ?Erosive Esophagitis?: Oral formulations for mucosal repair and symptom control.

• ?Peptic Ulcers?: Reduces gastric and duodenal ulcer recurrence rates.

• ?H. pylori Therapy?: Synergistic use with antibiotics for higher eradication success.

• ?Drug Development?: Intermediate for novel P-CAB-based therapies.

?? ?Quality Assurance?

• ?Testing Standards?: Complies with ?USP/EP? pharmacopeial guidelines.

• ?Analytical Methods?: Validated via ?HPLC, NMR?, and ?mass spectrometry?.

• ?Packaging?: Customizable batches (10mg–1kg) with moisture-proof, light-protected containers.

?? ?Market Insights?

The global gastroesophageal reflux disease (GERD) therapeutics market is projected to grow at ?6.5% CAGR (2025–2030)?, driven by rising demand for non-PPI therapies. Asia-Pacific leads P-CAB API production, with South Korea and China dominating innovation and cost-efficient manufacturing.